Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Classement en actions #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Prix de l'action
$17.82
Dernière synchronisation: 2026-09-11
Capitalisation boursière
$32.43B
Changement (1 jour)
0.83%
Changement (1 an)
-25.31%
Pays
JP
Échange Daiichi Sankyo Company, Limited (4568)

Catégorie

Marge opérationnelle de Daiichi Sankyo Company, Limited (4568)
Marge opérationnelle au September 2026 TTM : 8.83%
Selon les derniers rapports financiers et le cours de l'action de Daiichi Sankyo Company, Limited, la marge opérationnelle actuelle (TTM) est de 8.83%. À la fin de 2024, elle était de 11.50%.
Historique de la marge opérationnelle pour Daiichi Sankyo Company, Limited de 2000 à 2026
Marge opérationnelle à la fin de chaque année
Année Marge opérationnelle Changez
2026 (TTM) 8.83% -45.09%
2025 16.08% 39.83%
2024 11.50% 43.93%
2023 7.99% -42.85%
2022 13.98% 5.43%
2021 13.26% -53.10%
2020 28.27% 56.97%
2019 18.01% 13.34%
2018 15.89% -14.66%
2017 18.62% -29.58%
2016 26.44% 63.31%
2015 16.19% 21.64%
2014 13.31% 32.17%
2013 10.07% -3.73%
2012 10.46% -17.18%
2011 12.63% 25.92%
2010 10.03% -4.93%
2009 10.55% -40.80%
2008 17.82% 21.47%
2007 14.67% -12.21%
2006 16.71% 15.64%
2005 14.45% -9.80%
2004 16.02% 14.35%
2003 14.01% -4.63%
2002 14.69% -8.81%
2001 16.11% -33.43%
2000 24.20% 0.00%
Marge opérationnelle pour des entreprises similaires ou concurrentes
Entreprise Marge opérationnelle Différence de Marge Opérationnelle Pays
43.92% -95.03%
US
26.81% -96.96%
US
29.32% -96.68%
US
26.59% -96.99%
CH
16.65% -98.11%
US
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.